Burkina Faso vs Eswatini: Access to anti-retroviral drugs, female
Burkina Faso
98.0%
in 2024
Eswatini
98.0%
in 2024
Burkina Faso rank
1st
Eswatini rank
1st
Access to anti-retroviral drugs, female over time
- Burkina Faso
- Eswatini
How they compare
Burkina Faso currently reports 98.0% against 98.0% in Eswatini, a difference of 0.0%.
The two have swapped places 4 times across 25 shared years of data; in 2000 it was Eswatini ahead.
Burkina Faso ranks 1st and Eswatini ranks 1st of 141 countries.
Across the 3 decades both report, Burkina Faso averaged higher in 2 and Eswatini in 1.
Head to head by decade
| Decade | Burkina Faso | Eswatini | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 10.1% | 7.7% | 2.4% | Burkina Faso |
| 2010s | 67.6% | 64.4% | 3.2% | Burkina Faso |
| 2020s | 91.8% | 97.4% | 5.6% | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Burkina Faso or Eswatini?
- Burkina Faso, at 98.0% against 98.0% in Eswatini as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Burkina Faso and Eswatini?
- 0.0%, with Burkina Faso ahead.
- How many years of comparable data are there for Burkina Faso and Eswatini?
- 25 years are reported by both, from 2000 to 2024.
- How do Burkina Faso and Eswatini rank globally for access to anti-retroviral drugs, female?
- Burkina Faso ranks 1st and Eswatini ranks 1st of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.